TD Cowen analyst Stacy Ku maintained a Buy rating on Astria Therapeutics (ATXS – Research Report) today and set a price target of $35.00. The company’s shares closed yesterday at $9.75.
Ku covers the Healthcare sector, focusing on stocks such as Astria Therapeutics, Supernus Pharmaceuticals, and Aurinia Pharmaceuticals. According to TipRanks, Ku has an average return of -2.0% and a 52.38% success rate on recommended stocks.
Astria Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.83, implying a 154.67% upside from current levels. In a report released on November 14, Oppenheimer also maintained a Buy rating on the stock with a $28.00 price target.
ATXS market cap is currently $550.2M and has a P/E ratio of -4.66.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Astria Therapeutics (ATXS) Company Description:
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.
